Effect of obesity on COX1 and 2 acetylation by aspirin as a biomarker of its efficacy in colon cancer chemoprevention and therapy. - Trial 2021-005999-18
Access comprehensive clinical trial information for 2021-005999-18 through Pure Global AI's free database. This phase not specified trial is sponsored by Instituto de Investigación Sanitaria Aragón and is currently Ongoing. The study focuses on Colorectal cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2021-005999-18
Ongoing
Trial Details
EU Clinical Trials Register • 2021-005999-18
Effect of obesity on COX1 and 2 acetylation by aspirin as a biomarker of its efficacy in colon cancer chemoprevention and therapy.
Study Focus
Sponsor & Location
Instituto de Investigación Sanitaria Aragón
Instituto de Salud Carlos III
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
-Allergy to acetylsalicylic acid or other NSAIDs.
ICD-10 Classifications
Malignant neoplasm of colon
Malignant neoplasm: Descending colon
Malignant neoplasm: Colon, unspecified
Malignant neoplasm: Ascending colon
Malignant neoplasm: Overlapping lesion of colon
Data Source
EU Clinical Trials Register
2021-005999-18
Non-Device Trial